Apogee Therapeutics is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. Co.'s pipeline is comprised of four programs being developed initially for the treatment of I&I indications. Co.'s two primary programs, APG777 and APG808, which Co. is initially developing for the treatment of AD and COPD, respectively. Moreover, Co. is evaluating APG777 in additional I&I indications, including asthma, areata, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, eosinophilic esophagitis and prurigo nodularis. We show 3 historical shares outstanding datapoints in our APGE shares outstanding history coverage, used to compute APGE market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing APGE market cap history over the course of time is important for investors
interested in comparing APGE's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of APGE versus a peer is one thing; comparing
APGE market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like APGE can fluctuate over the course of history.
With this page we aim to empower investors researching APGE by allowing them to research the APGE market cap history. |
Free APGE Email Alerts:
Video: The Importance of Market Cap
